A Phase II, Double-Blind, Randomized, Placebo-controlled, Clinical Study of PH3 for the Prevention of Osteoporosis in Postmenopausal Women.
Latest Information Update: 12 Nov 2011
Price :
$35 *
At a glance
- Drugs PHN 031 (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- 03 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Nov 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 17 Aug 2008 Inclusion and exclusion criteria updated as reported by ClinicalTrials.gov.